Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Regeneron Pharmaceuticals's gross profit for the twelve months ending Mar 31, 2018 was $5.85B, up 21.9% year over year. For fiscal 2019 it was $6.15B, up 25.4% from the year before. Over ten years it grew 32.2% a year on average. The highest annual figure on record is $6.15B in fiscal 2019.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $6.15B | +25.4% |
| FY2018 | Dec 31, 2018 | $4.91B | -13.4% |
| FY2017 | Dec 31, 2017 | $5.67B | +21.5% |
| FY2016 | Dec 31, 2016 | $4.67B | +20.8% |
| FY2015 | Dec 31, 2015 | $3.86B | +43.5% |
| FY2014 | Dec 31, 2014 | $2.69B | +35.4% |
| FY2013 | Dec 31, 2013 | $1.99B | +53.5% |
| FY2012 | Dec 31, 2012 | $1.29B | +193.1% |
| FY2011 | Dec 31, 2011 | $441.61M | -3.4% |
| FY2010 | Dec 31, 2010 | $456.98M | +21.0% |
| FY2009 | Dec 31, 2009 | $377.58M | +59.0% |
| FY2008 | Dec 31, 2008 | $237.53M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2018 | Mar 31, 2018 | $1.44B | +14.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.53B | +29.4% |
| Q3 FY2017 | Sep 30, 2017 | $1.45B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.43B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.26B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.18B | – |
See a number that looks wrong?